Cannabinoid Supplementation on Vascular and Cognitive Function
Mo kle
Abstrè
Dat
| Dènye verifye: | 09/30/2019 |
| Premye Soumèt: | 09/19/2017 |
| Enskripsyon Estimasyon Soumèt: | 09/21/2017 |
| Premye afiche: | 09/27/2017 |
| Dènye Mizajou Soumèt: | 10/20/2019 |
| Dènye Mizajou afiche: | 10/22/2019 |
| Dat aktyèl kòmanse etid la: | 12/31/2017 |
| Dat Estimasyon Prensipal Estimasyon an: | 09/29/2021 |
| Dat estime fini etid la: | 09/30/2021 |
Kondisyon oswa maladi
Entèvansyon / tretman
Dietary Supplement: Cannabidiol supplement
Faz
Gwoup bra
| Bra | Entèvansyon / tretman |
|---|---|
| Placebo Comparator: Placebo Sugar pill that will have no effect. | |
| Active Comparator: Cannabidiol and herbal capsules (1 dose) Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil. | |
| Active Comparator: Cannabidiol (1 dose) Only cannabidiol supplement. | |
| Active Comparator: Cannabidiol and herbal capsules (2 dose) Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil. | |
| Active Comparator: Cannabidiol only (2 dose) Only cannabidiol supplement. |
Kritè kalifikasyon yo
| Laj ki kalifye pou etid | 18 Years Pou 18 Years |
| Sèks ki kalifye pou etid | All |
| Aksepte Volontè Healthy | Wi |
| Kritè | Inclusion Criteria: - non-smoking - non-obese - between the ages of 18-30 & 60-75 years - have no history of cardiopulmonary, liver, gastrointestinal, kidney or cerebrovascular disease. Exclusion Criteria: - are obese - are taking prescription drugs or over-the-counter supplements that influence cardiovascular or nitric oxide metabolism - have a history of smoking - have history of cardiovascular, respiratory (including asthma) or neurological disease - have known intolerance to ginseng or ginkgo herbals - have kidney, gastrointestinal or liver disease - have epilepsy - have diabetes - are pregnant or breast feeding - do not speak English as first language - a student in the University of British Columbia (UBC) Okanagan Centre for Heart, Lung and Vascular Health - medical or recreational use of cannabis - clinically diagnosed anxiety or depression - history of opioid use - unwilling or unable to execute the informed consent documentation |
Rezilta
Mezi Rezilta Prensipal yo
1. Circulating cannabidiol and nitric oxide markers [Through study completion, an average of 1 year]
2. Vascular function [Through study completion, an average of 1 year]
Mezi Rezilta Segondè
1. Height [Through study completion, an average of 1 year]
2. Weight [Through study completion, an average of 1 year]
3. Body mass index [Through study completion, an average of 1 year]
4. Systolic blood pressure [Through study completion, an average of 1 year]
5. Diastolic blood pressure [Through study completion, an average of 1 year]
6. Heart rate [Through study completion, an average of 1 year]
7. Respiration [Through study completion, an average of 1 year]
8. Medical History Questionnaire [Through study completion, an average of 1 year]
9. Gastrointestinal Distress Questionnaire [Through study completion, an average of 1 year]
10. Anxiety Questionnaire [Through study completion, an average of 1 year]
11. Cognitive performance [Through study completion, an average of 1 year]
12. Exercise performance [Through study completion, an average of 1 year]
